Clinical Trials Logo

Docetaxel clinical trials

View clinical trials related to Docetaxel.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06374914 Not yet recruiting - Bladder Cancer Clinical Trials

Sequential Intravesical Gemcitabine and Docetaxel for Rescue Therapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Patients

Start date: April 9, 2024
Phase:
Study type: Observational

Studies in the literature are limited both throughout Turkey and in general. For this reason, as a result of the study that we will create, it will provide us with information for bladder protective treatments in patients who do not respond to BCG therapy in bladder cancer patients.

NCT ID: NCT03589950 Not yet recruiting - Lung Neoplasms Clinical Trials

Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer

Start date: August 1, 2018
Phase: Phase 2
Study type: Interventional

Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration(SFDA:2011L00661) which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2、VEGFR3、PDGFRβ and c-Kit. It has the obvious resistance to new angiogenesis. The trial is to explore Anlotinib for the effectiveness and safety of advanced non-small cell lung cancer who failed first lines of chemotherapy